RaDIANT Health Systems Intervention (NCT07033117)
The RaDIANT Health Systems Intervention for Improving Access to Kidney Transplantation
🩺 Plain-English Summary (8th-Grade Level)
The overarching goal of the proposed study is to determine whether the addition of structural interventions at the health system level targeting upstream barriers in the transplant process will improve access to transplant evaluation start.
Who can join: Review the eligibility criteria below.
Location: Piedmont Transplant Institute — Atlanta, Georgia
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Performance Feedback Reports on Referral and Evaluation Closures (OTHER)
- Dialysis Facility Awareness Campaign (OTHER)
- Patient Contact via Preferred Method (OTHER)
- Phone Call to Dialysis Facility During the Patient's Dialysis Session (OTHER)
- Phone Call to Provider (OTHER)
- Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show (OTHER)
- Audit and Tracking of Patient Contact Attempts Prior to Referral Closure (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Piedmont Transplant Institute — Atlanta, Georgia
- Emory Transplant Center — Atlanta, Georgia
- IU Health Transplant - Indianapolis — Indianapolis, Indiana
- Duke Transplant Center — Durham, North Carolina
- MUSC Mid-Carolinas Transplant Center — Lancaster, South Carolina
📞 Contact the Study Coordinator
Phone: (404) 605-4600
Email: ana.rossi@piedmont.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End Stage Renal Disease (ESRD)
- Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure — Rochester, Minnesota
- Outcome of BCF Access in Hemodialysis Patients — Chicago, Illinois
- To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis — Scottsdale, Arizona
- Multi-Site STARgraft (10401) Trial — Brasília,
- Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal — Mexico City, Mexico City
- A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease — Phoenix, Arizona
Explore by condition: All End Stage Renal Disease (ESRD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.